EUVIMEDEUVIMED entdecken
Fallbericht

Low Dose Sucralfate Associated With Significantly Reduced Warfarin INR Response: A Case Report

Randolph E Regal iD, Sarah K Adie iD

Journal of Pharmacy Practice · 08.07.2026

DOI: 10.1177/08971900261469308 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 08.07.2026. Verfasst von Randolph E Regal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Adult Internal Medicine, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sucralfate is a medication that is a chemical complex consisting of aluminum hydroxide and sulfated sucrose. It has been found to cause malabsorption of many different medications, including warfarin, by chelating the drugs within the gastrointestinal (GI) lumen. To minimize potential malabsorption interactions, it is recommended that there be at least a two-hour separation between administration of sucralfate and the second drug. This case report involved a hospitalized patient who was also monitored once discharged, then rechallenged and de-challenged with low dose sucralfate at doses of only 1 gram once daily or 1g twice daily. The case showed that warfarin requirements approximately doubled when the drugs were used concomitantly vs warfarin alone. When the medications were given in the first hospitalization, once daily sucralfate was given at 0900 and warfarin at 2100. Thus, even though the drugs were being separated by about 12 hours, it appears the interaction still manifested. When sucralfate was increased to twice daily in the second hospitalization, it was dosed at 0900 and 2100. Of course, warfarin was also given at 2100 each day for the second admission. Around both hospitalizations, the challenge with sucralfate resulted in subtherapeutic warfarin levels, thereby necessitating dose escalation well above “pre-sucralfate” doses to achieve International Normalized Ratios (INRs) in the therapeutic range of 2-3 for this patient. Also, around both hospitalizations, de-challenge of sucralfate resulted in INRs becoming supratherapeutic in just 2-3 days, yielding INRs of 8.1 after the first discharge and 5.4 after the second discharge.

Schlagwörter

Stichwörter der Autor:innen

drug interactionmalabsorption interactionssucralfatewarfarin

Autor:innen und Institutionen

  • Department of Pharmacy, Adult Internal Medicine, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
  • Department of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.

ORCID-Profile: Randolph E Regal, Sarah K Adie

Zitieren

APA

Regal, R. E., & Adie, S. K. (2026). Low Dose Sucralfate Associated With Significantly Reduced Warfarin INR Response: A Case Report. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900261469308

Vancouver

Regal RE, Adie SK. Low Dose Sucralfate Associated With Significantly Reduced Warfarin INR Response: A Case Report. Journal of Pharmacy Practice. 2026. doi:10.1177/08971900261469308

BibTeX
@article{Regal2026,
  author = {Regal, Randolph E and Adie, Sarah K},
  title = {Low Dose Sucralfate Associated With Significantly Reduced Warfarin INR Response: A Case Report},
  journal = {Journal of Pharmacy Practice},
  year = {2026},
  doi = {10.1177/08971900261469308}
}
Kostenlos starten →